OncoMatch/Clinical Trials/NCT03193567
Study of High Efficient Killing Cell Therapy for Advanced NSCLC
Is NCT03193567 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies HEKT cell for non small cell lung cancer.
Treatment: HEKT cell — The purpose of this study to preliminarily evaluate the safety and efficacy of High Efficient Killing Cell Therapy for refractory and advanced non-small cell lung cancer
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Performance status
KARNOFSKY 0–1
Prior therapy
Must have received: standard chemotherapy
failed in previous standard chemotherapy
Must have received: targeted therapy
failed in previous...targeted therapy
Lab requirements
Kidney function
adequate organ functions; severe renal dysfunction excluded
Liver function
adequate organ functions; severe hepatic dysfunction excluded
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify